financetom
Business
financetom
/
Business
/
Bumble Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bumble Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Mar 11, 2026 7:28 AM

Bumble Inc. ( BMBL ) will release earnings results for its fourth quarter, after the closing bell on Wednesday, March 11.

Analysts expect the Austin, Texas-based company to report quarterly earnings at 21 cents per share, down from 30 cents per share in the year-ago period. The consensus estimate for Bumble's quarterly revenue is $221.45 million, versus $261.65 million a year earlier, according to data from Benzinga Pro.

On Nov. 5, Bumble issued fourth-quarter sales guidance below estimates.

Bumble shares fell 5.1% to close at $2.81 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Citigroup analyst Ygal Arounian maintained a Neutral rating and cut the price target from $5.5 to $3.8 on Dec. 22, 2025. This analyst has an accuracy rate of 63%.

Jefferies analyst James Heaney maintained a Hold rating and lowered the price target from $5 to $4 on Dec. 11, 2025. This analyst has an accuracy rate of 66%.

UBS analyst Kunal Madhukar maintained a Neutral rating and slashed the price target from $6.5 to $5 on Nov. 10, 2025. This analyst has an accuracy rate of 71%.

Susquehanna analyst Shyam Patil maintained a Neutral rating and cut the price target from $7 to $4.5 on Nov. 10, 2025. This analyst has an accuracy rate of 64%.

Evercore ISI Group analyst Shweta Khajuria maintained an In-Line rating and cut the price target from $7 to $5 on Nov. 7, 2025. This analyst has an accuracy rate of 61%.

Considering buying BMBL stock? Here’s what analysts think:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved